Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 53.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 6.36M |
| Shares Out | 4.84M |
| EPS (ttm) | 1.31 |
| PE Ratio | 8.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RGNT
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. Our lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC wa... [Read more]
News
Israeli hydrogel implant developer Regentis Biomaterials files and sets terms for a $10 million US IPO
Regentis Biomaterials, an Israeli regenerative medicine company developing orthopedic hydrogel implants, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering.
Regentis Biomaterials IPO Registration Document (F-1)
Regentis Biomaterials has filed to go public with an IPO on the NASDAQ.